advertisement
Abstract #8255 Published in IGR 4-3
Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure
Jampel HD; Bacharach J; Sheu WP; Wohl LG; Solish AM; Christie WAmerican Journal of Ophthalmology 2002; 134: 863-871
PURPOSE: To compare the intraocular pressure (IOP)-lowering effect and safety of latanoprost 0.005% once daily with that of unoprostone 0.15% twice daily for patients with primary open-angle glaucoma or ocular hypertension. DESIGN: Randomized clinical trial. METHODS: In a prospective, eight-week, investigator-masked, parallel-group study conducted at numerous centers in the USA, 165 previously treated patients with IOP ≥ 25 mmHg in one or both eyes after washout were randomly assigned to receiving either latanoprost 0.005% once daily in the evening or unoprostone 0.15% twice daily. Observation procedures were Goldmann applanation tonometry, best-corrected visual acuity, slit-lamp biomicroscopy, and ophthalmoscopy. The main outcome measure was change in the mean of the IOPs measured at 8:00 a.m., 12 noon, and 4:00 p.m. between baseline (before treatment) and after eight weeks of treatment. RESULTS: The change in the mean ± SD of the IOPs measured at 8:00 a.m., 12 noon, and 4:00 p.m. was -7.2 ± 3.2 mmHg (28%) for latanoprost (25.3 ± 2.8 mmHg at baseline to 18.2 ± 2.8 mmHg at eight weeks) and -3.9 ± 2.6 mmHg (15%) for unoprostone (25.5 ± 3.3 mmHg at baseline to 21.6 ± 4.0 mmHg; p ≤ 0.001). No serious adverse event related to either medication was reported. CONCLUSIONS: Over an eight-week period, latanoprost 0.005% once daily lowered IOP more than unoprostone 0.15% twice daily in patients with elevated IOP. Both agents were safe and well tolerated.
H.D. Jampel, MD, Department of Ophthalmology, Johns Hopkins University School of Medicine, 600 N Wolfe Street, Baltimore, MD 21287-9205, USA. hjampel@jhmi.edu
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
